» Articles » PMID: 14755541

Simultaneous Activation of Several Second Messengers in Hypoxia-induced Hyperpermeability of Brain Derived Endothelial Cells

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2004 Feb 3
PMID 14755541
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

In vivo, ischemia is known to damage the blood-brain barrier (BBB) leading to the development of vasogenic brain edema. Hypoxia-induced vascular endothelial growth factor (VEGF) has been shown to be a key regulator of these permeability changes. However, the signaling pathways that underlie VEGF-induced hyperpermeability are incompletely understood. In this study, we demonstrate that hypoxia- and VEGF-induced permeability changes depend on activation of phospholipase Cgamma (PLCgamma), phosphatidylinositol 3-kinase/Akt (PI3-K/Akt), and protein kinase G (PKG). Inhibition of mitogen-activated protein kinases (MAPK) and of the protein kinase C (PKC) did not affect permeability at all. Paralleling hypoxia- and VEGF-induced permeability changes, localization of the tight junction proteins occludin, zonula occludens-1 (ZO-1), and ZO-2 along the cell membrane changed from a continuous to a more discontinuous expression pattern during hypoxia. In particular, localization of ZO-1 and ZO-2 expression moved from the cell membrane to the cytoplasm and nucleus whereas occludin expression remained at the cell membrane. Inhibition of PLCgamma, PI3-kinase, and PKG abolished these hypoxia-induced changes. These findings demonstrate that hypoxia and VEGF induce permeability through rearrangement of endothelial junctional proteins which involves activation of the PLCgamma and PI3-K/AKT pathway leading to the activation of PKG.

Citing Articles

The Basic Requirement of Tight Junction Proteins in Blood-Brain Barrier Function and Their Role in Pathologies.

Dithmer S, Blasig I, Fraser P, Qin Z, Haseloff R Int J Mol Sci. 2024; 25(11).

PMID: 38891789 PMC: 11172262. DOI: 10.3390/ijms25115601.


Stroke-induced damage on the blood-brain barrier.

Xue S, Zhou X, Yang Z, Si X, Sun X Front Neurol. 2023; 14:1248970.

PMID: 37840921 PMC: 10569696. DOI: 10.3389/fneur.2023.1248970.


A NIR-responsive indocyanine green-genistein nanoformulation to control the polycomb epigenetic machinery for the efficient combinatorial photo/chemotherapy of glioblastoma.

Kaundal B, Srivastava A, Sardoiwala M, Karmakar S, Roy Choudhury S Nanoscale Adv. 2022; 1(6):2188-2207.

PMID: 36131972 PMC: 9419092. DOI: 10.1039/c9na00212j.


In Vitro Models of the Human Blood-Brain Barrier Utilising Human Induced Pluripotent Stem Cells: Opportunities and Challenges.

Pervaiz I, Al-Ahmad A Methods Mol Biol. 2022; 2492:53-72.

PMID: 35733038 DOI: 10.1007/978-1-0716-2289-6_3.


The Bradykinin B2 Receptor Agonist (NG291) Causes Rapid Onset of Transient Blood-Brain Barrier Disruption Without Evidence of Early Brain Injury.

Rodriguez-Masso S, Erickson M, Banks W, Ulrich H, Martins A Front Neurosci. 2022; 15:791709.

PMID: 34975388 PMC: 8715084. DOI: 10.3389/fnins.2021.791709.